Abstract
Lactobacillus brevis (L. brevis) is a widely used probiotic with health-promoting properties. Previous studies reported that L. brevis has beneficial impacts on T2DM mice. On the other hand, the differences in effects between live and inactivated L. brevis are still inconclusive. This study aims to evaluate the hypoglycemic effects of inactivated L. brevis YM1301 (YM1301) on T2DM mice induced by a high-fat diet (HFD) combined with streptozocin (STZ). T2DM mice were randomly stratified into four groups and administered either saline (model group), metformin (positive control group), live YM1301 (LB group), or inactivated YM1301 (ILB group). Results demonstrated that inactivated YM1301 reduced serum content of fasting blood glucose, insulin, and glycated hemoglobin, enhanced the level of glucose tolerance, and decreased insulin resistance in T2DM mice. Inactivated YM1301 also decreased fat accumulation in T2DM mice. In addition, inactivated YM1301 effectively promoted serum GLP-1 levels. These results showed that inactivated YM1301 can significantly improve symptoms of T2DM. This study provides theoretical feasibility for the development of low-cost, easy to store, safer, and more effective probiotic products related to L. brevis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
